Purpose: The cost-effectiveness of first-line chronic lymphocytic leukemia treatments was assessed among patients unsuitable for full doses of fludarabine.
time incremental cost-effectiveness ratio (ICER) (euro/quality-adjusted life-year [QALY] gained) with an annual 3% discounting. A probabilistic Markov model with 3 health states (progression-free, progression, and death) was developed. Survival time was modeled based on age-matched clinical data by using appropriate survival distributions. Each health state was assigned an EuroQoL-5D-3L quality-of-life estimate and Finnish payer costs according to treatment received, and Binet stage of disease; severe adverse events and treatment inconvenience were also included. Six approaches considered the risk and value of key outcomes: cost-effectiveness efficiency frontiers; Bayesian treatment ranking (BTR) rated the lowest ICERs and best QALY gains; the cost-effectiveness acceptability frontier demonstrated optimal treatment; expected value of perfect information; and the costbenefit assessment (CBA), a type of clinical value analysis, increased the clinical interpretation and appeal of modeled outcomes by including both relative and absolute (impact investment [benefit obtained with a fixed limited budget]) benefit assessments.
Findings: The ICERs compared with chlorambucil varied from €29,334 with obinutuzumab þ chlorambucil to €82,159 with ofatumumab þ chlorambucil. Based on the BTR of ICERs versus chlorambucil, obinutuzumab þ chlorambucil was the most cost-effective with 93% probability; rituximab þ chlorambucil was the second most cost-effective (73%); and rituximab þ bendamustine was the third most cost-effective (65%). The ICERs of obinutuzumab þ chlorambucil were €20,038, €11,556, and €15,586 compared with rituximab þ chlorambucil, rituximab þ bendamustine, and ofatumumab þ chlorambucil. Obinutuzumab þ chlorambucil was the most cost-effective treatment, with 54% and 99% probability at €30,000 and €50,000/ QALY gained, respectively. The corresponding expected values of perfect information were €1438 and €44 per patient. Based on the BTR of QALYs gained, obinutuzumab þ chlorambucil was the most effective, with 100% probability; rituximab þ chlorambucil was the second most effective (56%); and rituximab þ bendamustine was the third most effective treatment (81%). Results were robust in sensitivity analyses. For obinutuzumab þ chlorambucil, the CBA demonstrated the best clinical value-to-cost-effectiveness relation and the longest time progression-free with a limited budget.
Implications: The mean results were sensitive to large changes in time horizon, indirect comparison hazard ratios, survival distributions, and discounting; however, obinutuzumab þ chlorambucil provided considerable effectiveness and best value for money among chronic lymphocytic leukemia patients unsuitable to
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia, accounting for 25% to 40% of all leukemias. 1, 2 The annual incidence of CLL is 2 to 6 per 100,000 population, 1,3 with a preponderance of male subjects over female subjects. CLL is more common in elderly people, with almost one half of the newly diagnosed CLL patients being at least 75 years of age. CLL causes significant humanistic [4] [5] [6] [7] [8] [9] [10] and economic 9, 11, 12 burdens.
Immunochemotherapy with rituximab þ fludarabine þ cyclophosphamide (RFC) has been the standard first-line treatment for patients with CLL who require and can tolerate intense chemotherapy. However, older patients with comorbidities are often ineligible for RFC. 13 For these patients, chlorambucil monotherapy (Clb) is often used, even though it rarely induces complete responses. [14] [15] [16] Currently, combination regimens, including obinutuzumab þ chlorambucil (GClb), ofatumumab þ chlorambucil (OClb), rituximab þ bendamustine (RB), and rituximab þ chlorambucil (RClb), are considered because of their efficacy and limited toxicity.
The present study is the first to estimate the costeffectiveness of all relevant treatments among patients with CLL unsuitable for full-dose fludarabine and, thus, RFC therapy to the best of our knowledge. It is also probably the first to elaborate on the results of a full health economic assessment involving 6 different methods: cost-effectiveness efficiency frontiers; Bayesian treatment ranking (BTR); cost-effectiveness acceptability frontier (CEAF); expected value of perfect information per patient (EVPI); limited cost-benefit assessment (CBA), which is a clinical value analysis; and impact investment analysis (IIA) based on the CBA.
MATERIALS AND METHODS
A decision-analytic modeling approach was used to conduct the cost-effectiveness analysis (CEA) presented here. This CEA meets the Finnish requirements for health economic evaluations, 17 which concurs with most European guidelines. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Clb, GClb, OClb, RB, and RClb were compared by using a probabilistic, long-term, Markov transition model ( Figure 1 ) with 3 mutually exclusive key health states in patients with CLL who were unsuitable for RFC. A 1-week model cycle length with life-table method of half-cycle correction 28,29 was applied.
Progression-free Survival
The CEA was based on individual patient data from CLL11 (An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 þ Chlorambucil (GClb) Compared to Rituximab þ Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities), including progression-free survival (PFS) for Clb, GClb, and RClb (March 3, 2014 data cut 16 ), and aggregated PFS from Knauf et al, 14 33 for RB. The CLL11 trial program had 2 stages for GClb and RClb, with stage 1 being a subgroup of stage 2. The stage 2 individual patient data from CLL11 were used for GClb and RClb. For Clb, only the stage 1 individual patient data were available. The baseline characteristics of patients in the key trials are reported in Supplemental Table I (as shown in the online version at http://dx.doi.org/10.1016/j.clinthera.2016.02.005). The key differences were as follows: the CLL11 patients were older, had more comorbidities, and had worse creatinine clearance compared with the COMPLEMENT 1 or CLL10 patients. Unlike the CLL11 and COMPLEMENT 1 patients, the CLL10 patients had a low Cumulative Illness Rating Scale, and the patients were basically suitable for fludarabine treatment. The dosing regimens of the trials are reported in the Costs section of this article.
All simulated cohort members started the model in the PFS health state, on treatment, and could progress, die, or discontinue treatment based on the actual treatment duration in line with the CLL11 results. Because the maximum treatment duration was 6 cycles in CLL11, parametric survival functions were not used for treatment duration, but the actual proportions of patients on treatment from CLL11 were used.
Weibull's parametric survival distribution was selected to model the CLL11 PFS based on statistical tests, the Akaike information criterion, visualization, and expected PFS times from longer term clinical studies. The following parameter values (SEs) were used: Clb intercept, 2.591 (0.065); Clb scale, 0.636 (0.049); GClb intercept 3.628 (0.057); GClb scale, 0.635 (0.046); RClb intercept, 3.070 (0.036); and RClb scale, 0.560 (0.029). Cholesky decomposition was applied to include the correlation of survival model parameters. 34 For the comparison versus OClb and RB, a Bayesian meta-analysis 35 with age adjustment was available. The hazard ratios (HRs) were converted into logarithmic HRs to inform probabilistic sensitivity analysis distributions, and they were used to adjust the PFS estimates of RB and OClb: GClb versus RB, HR of 0.412 (lnHR, -0.937; SD, 0.314); GClb versus OClb, HR of 0.295 (lnHR, -1.241; SD, 0.203).
The probability of death during PFS was the maximum of death rate in CLL11 and the Finnish age-and gender-specific mortality in 2013. 36, 37 Survival curves are depicted in Figure 2 .
Postprogression Survival
After progression, the proportion of cohort members with Binet stages A, B, and C were 14.5%, 47.2%, and 37.8%, respectively. 38 Postprogression survival (PPS), the transition from progressive disease to death, was modeled based on the CLL5 (Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia) trial (January 14, 2013, data-cut) due to immaturity of overall survival and crossover in CLL11. Applicability was ascertained by taking into account the age of patients at the time of disease progression by using an exponential parametric survival model with age as a covariate (SE): intercept, 6.492 (1.920); age, -0.035 
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(0.027). The exponential model was selected based on the Akaike information criterion, visual inspection, and expected overall survival from longer term clinical studies and Finnish data. 39 Cholesky decomposition 34 was applied for PPS.
Costs
Direct health state-specific costs were applied based on the treatments and Binet stages ( Table I) . Costs consisted of drug acquisition, drug administration, monitoring, follow-up, progression/relapse resources, postprogression treatment, and treatment of serious adverse events (SAEs). Indirect costs and losses such as absenteeism, presenteeism, caregiver and time costs, and disutilities due to informal care were ignored according to the Finnish guidance 17 and CLL11 mean patient age exceeding the Finnish retirement age.
Drugs
The actual treatment duration and dosing from the trials were used without vial sharing. Furthermore, a distinction was made between the first and consecutive drug administrations and is shown in Table I , which also reports the dosing regimens from the trials. The first dose of obinutuzumab may be given on 1 day or split over 2 consecutive days. Not benefiting obinutuzumab in terms of administration costs, 1 vial split to 100 mg day 1 and 900 mg day 2, and consequent higher drug administration cost was assumed (ie the 1000 mg vial may be given in day 1 and lower drug administration may be used). Up-to-date costs [40, 41] were used together with the cost correction for administration time needed in order not to underestimate the administration cost of intravenous drugs (see [42] ).
Individual patient drug utilization data were available for Clb, GClb, and RClb. For OClb, the estimated treatment duration was, on average, 6.4 cycles of a planned 12 cycles (ie, 53.3%) 32 with 100% assumed dose intensity. For RB, the mean number of treatment cycles was 5.41 of a planned 6.00. 33 The mean dose was estimated to be 96.84% (ie, 90.0% * 31.6% þ 100% * 68.4% based on Eichhorst et al 33 ). Postprogression cancer drugs were based on CLL5 (6.5 months of Clb 0.5 mg/kg 38 together with administration/monitoring costs).
Adverse Events
Grade 3 to 5 SAEs observed in CLL11 individual patient data, COMPLEMENT 1, 32 and CLL10 33 were included based on their potential association with CLL treatment. For OClb and RB, a maximum 1 SAE/preferred term was included, 32,33 whereas for Clb, GClb, and RClb, multiple SAEs/preferred term or patient was possible. This inconsistency resulting from the publications benefited OClb and RB compared with Clb, GClb, or RClb. All expected SAE costs ( Supplemental Table II 
Binet and End-stage
The resources were partitioned based on Binet stages. Based on the Finnish experience, the following annual resources were fixed for all: 1 primary care visit (€116.18), 1 specialist visit (€309.04), and a comprehensive blood test. 40, 41 In addition, the following factors were considered annually: Binet stage A, 2.67 primary care calls (€27.46/call) and 4.80 calls if progressed; Binet stage B, 3.00 primary care calls (4.80 calls and 1 specialist visit if progressed); and Binet stage C, 4.80 primary care calls and 1 specialist visit. One blood cell count þ neutrophil assessment per visit were included.
Based on the Finnish experience, end-stage treatment consisted of pneumonia in 40% of patients (€7827.49 per hospitalization 40, 41 ); autoimmune hemolytic anemia or immune thrombocytopenia in 5% of patients 13 (10-day hospital stay for autoimmune hemolytic anemia/immune thrombocytopenia, €6205.06 40, 41 ); and 1 primary care call per week for the last 2 months (included as an expected cost during the PPS).
Quality-adjusted Survival
Patient utility was based on a recent UK utility elicitation study with validated health states and EuroQoL-5D-3L (EQ-5D-3L) dimensions. 10 The impact of on/off treatment on quality of life (QoL) was accounted for. The UK utility values based on elicitation were adjusted to take into account the representative EQ-5D-3L tool-based generic QoL of 65-to 74-year-old Finns together with their symptoms/comorbidities (adjusting factor 0.776/0.820 based on the EQ-5D-3L QoL of 65-to 74-year-old Finns per utility with PFS off-treatment [43] / [10] , 40, 41 ). Drugs 1 included corticosteroid prednisolon 100 mg IV, the antihistamine cetirizine 10 mg, and paracetamol PanadolR 1 g po. Drugs 2 included cetirizine 10 mg and paracetamol 1 g po. Drugs 3 included cetirizine 10 mg, paracetamol 1 g, and antiemetic metoclopramide 10 mg po. Drug costs were taken from the Finnish Medicines Tariff 9/2014.
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The mean (SD) QoL values were as follows: 0.672 (0.189) PFS with nonintravenous treatment, 0.634 (0.208) PFS with intravenous treatment, 0.520 (0.246) PFS with increased hospital visits, 0.776 (0.181) PFS offtreatment (mean equivalent to the EQ-5D-3L QoL of 65to 74-year-old Finns 43 ), and 0.563 for PPS. Treatment inconvenience was assumed to last the longest between 2 planned treatment administrations (eg, GClb 4 weeks). The disutility due to increased hospital visits affected only GClb, although administration of RB and RClb can also be associated with multiple visits.
Time Horizon
Health outcomes should be modeled over the remaining lifetime of the patients 34 if a mortality difference is expected. With the base-case settings, 1.7% of the GClb cohort was predicted to be alive within 20 years, and thus a 20-year time horizon was used. Adhering to the Finnish guidelines, 17 all outcomes were discounted with 3% per year.
Distributions
The second-order Monte Carlo simulation with 2000 simulations was conducted by using Visual Basic for Applications for Microsoft Excel 2013 (Microsoft Corporation, Redmond, Washington) and was used to jointly take into account variation in the outcomes due to potential sampling uncertainty related to the model parameters. β-Distributions were used for QoL values, multivariate normal distributions for parametric PFS and PPS based on individual patient data, and log-normal distributions for SAE amounts, costs, and PFS HRs. In case of unknown SE, Ϯ20% of mean value was used.
Outcomes
The primary outcome of the analysis was costutility measured as the incremental cost-effectiveness ratio (ICER), which is the ratio of the cost and qualityadjusted life-year (QALY) difference between 2 interventions. The ICERs were determined versus the most affordable and the most efficient option. The efficient nondominant options were also depicted as the costeffectiveness efficiency frontier. 44 Bayesian treatment ranking (BTR) was used to incorporate risk assessment to the ranking of the lowest ICERs (best relative value with euro), best quality-adjusted survivals (highest QALY gains), and impact investing.
The secondary outcomes included incremental cost per life-year gained, uncertainty assessment in terms of the cost-effectiveness acceptability frontier (CEAF), and expected value of perfect information per patient (EVPI). The CEAF illustrates the optimal treatments with the highest expected monetary net benefit (pay-off) as a function of willingness-to-pay (euro/QALY gained). The EVPI demonstrates the maximum monetary value of total parameter uncertainty that can be resolved by acquiring perfect evidence for the included model parameters or alternatively the expected net monetary consequences related to a "wrong" resource allocation decision. [45] [46] [47] In Finland, the interpretation of costeffectiveness is complicated because the decision-maker's willingness-to-pay is not publicly announced, 48 and, thus, the CEAF and EVPI complement the primary outcomes. Based on our experience, the maximum willingness-to-pay for CLL would be approximately €50,000/QALY gained, and values less than €30,000/ QALY (€20,000/QALY) gained are likely to indicate good (very good) cost-effectiveness, respectively. These findings are in line with similar UK thresholds. 27 Because ICER and CEAF are sensitive to the number of comparators included (and EVPI may be also), results excluding Clb were also reported. 49 Clb may not be a relevant first-line treatment, and Clb results were based on stage 1 in CLL11.
To increase the clinical appeal and interpretation of CEA findings, the modeled primary and secondary results were used to develop tertiary results to complement them. The tertiary analysis approach was a CBA type (a form of clinical value analysis that could be labeled as drug cost-benefit approach), which essentially analyzes results during PFS and can include less extrapolation uncertainty in its limited perspective. Main CBAs were performed in terms of cost per QALY or PFS year gained during PFS (relative benefit assessment) and the length of benefit obtained with a fixed limited drug or PFS budget (absolute benefit assessment, impact investment) of €20,000 per patient. The impact investment analysis (IIA) incorporates an explicit willingness-to-invest value (ie, here assumed to be €20,000/patient) and thus illustrates the mean outcome in terms of a single unit (ie, time in years).
RESULTS
The ICERs (euro/QALY gained) compared with the most affordable treatment (Clb) were as follows: GClb, €29,334; RClb, €43,958; RB, €59,316; and OClb, €82,159. At the willingness-to-pay threshold of €30,000/QALY gained threshold, only GClb was costeffective compared with Clb. The ICERs for the most efficient option (GClb) compared with other combination treatments were below the most acceptable willingness-topay threshold (€11,556-€20,038) (Table II) . According to the cost-effectiveness efficiency frontier ( Figure 3 , Table II) , RClb, RB, and OClb were extendedly dominated by GClb and Clb. The ICERs for OClb versus Clb, and RB versus Clb, were €82,159 and €59,316, respectively, which may not be cost-effective.
Based on the conditional BTR of smallest ICER versus Clb (ie, the highest value for money), GClb was the most cost-effective (ie, efficient) treatment, with 92.9% probability; RB had 3.7% probability. The second most cost-effective treatments were RClb and RB, with probabilities of 72.8% and 21.7%, respectively. The third most cost-effective treatments were RB and OClb, with 65.2% and 34.8% probabilities. Consequently, GClb was the first best option, with only 7.1% risk of wrong allocation, RClb was second best option with 27.2% risk, and RB was third best option with 34.8% risk.
Secondary Outcomes
The average discounted survival ranged from 4.51 (Clb) to 5.75 (GClb) years ( Table II) . The discounted quality-adjusted survival ranged from 2.71 (Clb) to 3.75 (GClb) QALYs (Supplemental Figure 1 ), whereas the respective lifetime costs ranged from €12,159 to €42,467 (Supplemental Figure 2 ) (both as shown in the online version at http://dx.doi.org/10.1016/ j.clinthera.2016.02.005).
Based on the QALY and life-year differences, GClb was considerably more effective compared with the other treatments based on the 2.5% to 97.5% percentiles. Based on the BTR of greatest expected quality-adjusted survival (QALYs gained), GClb was the most effective, with 99.9% probability; RB had a probability of 0.1%. The second most effective treatments were RClb and RB, with 56.2% and 41.5% probabilities, respectively. The third most effective treatments were RB and OClb, with 81.1% and 18.9% probabilities. The fourth most effective rank was OClb, with 98.7% probability. Consequently, GClb is the first most effective option with only a 0.1% risk of wrong inference; RClb is the second most effective option, with a 43.8% risk; RB is third, with an 18.9% risk; and OClb is the fourth most effective option, with only 1.3% risk.
Costs for treatment acquisition (5%-64%), treatment administration/monitoring (10%-14%), and progression (18%-75%) were the biggest cost drivers for total costs (Supplemental Figure 2 [ 
Sensitivity Analyses for Primary and Secondary Outcomes
Multinomial cost-effectiveness acceptability curves were drawn (Supplemental Figure 3 [as shown in the online version at http://dx.doi.org/10.1016/j.clinthera. 2016.02.005). In summary, Clb and GClb constituted the CEAF ( Figure 4A ). At €30,000 and €50,000/ QALY gained, GClb had 54% and 99% probability for cost-effectiveness, respectively. The respective mean EVPIs were €1438 (2.5%-97.5% percentile, €0-€7379) and €44/patient, indicating low to moderate value of additional research to support decision-making or opportunity loss for a wrong Figure 3 . Cost-effectiveness plane with expected (discounted) lifetime costs, quality-adjusted life-years, and cost-effectiveness efficiency frontier (CEEF) (incremental cost-effectiveness ratio
decision. The maximum mean EVPI was €1739 per patient (€0-€8182).
Combination Treatment Comparison
OClb, RClb, and GClb constituted the CEAF in the comparison excluding Clb ( Figure 4B) . At €30,000 and €50,000/QALY gained, GClb had 90% and 99% probability for cost-effectiveness, respectively. The respective mean EVPIs were €204 (€0-€2797) and €42/patient, indicating very low value of additional research or loss for a wrong decision. The maximum mean EVPI was €1562/patient (€0-€7827).
Scenario Analyses
The relative base-case results were robust for various changes in method, population characteristic, efficacy, QoL, and cost inputs (Supplemental Appendix I [as shown in the online version at http:// dx.doi.org/10.1016/j.clinthera.2016.02.005]). Scenario analyses produced lower mean ICERs for GClb (difference in ICER, -2340), RClb (-913), and RB (-306), and a higher mean ICER for OClb (5466) compared with the deterministic base-case scenario.
Tertiary Outcomes
The tertiary objective was to elaborate on the primary and secondary outcomes by using CBA. Generally, CBA cannot fully substitute the primary outcomes of standard CEA, if CBA ignores all other than drug costs, differences in quality of life, differences in AEs, differences other than selected survival parameters (eg, overall survival or PFS depending on the selected approach), and concordance between costs and benefits (ie., costs and survivals are gained from different timelines). Consequently, compared with conventional standard CEA, CBA may result in a high level of ignorance.
Based on the CBA (Supplemental Appendix II [as shown in the online version at http://dx.doi.org/ 10.1016/j.clinthera.2016.02.005]), GClb had the highest relative clinical value, only a low risk for a high cost-benefit ratio, best clinical value-costeffectiveness relation, had the best impact on investment, and made the best value out of budget. In general, the CBA results concurred with the key outcomes, and the conclusions were similar.
DISCUSSION
This study illustrated the cost-effectiveness of first-line CLL treatments when RFC is unsuitable. The ICERs compared with Clb treatment (primary outcomes) were between €29,334 and €82,159/QALY gained, and GClb demonstrated the best value for money option and OClb demonstrated the worst. When ranked, GClb had the highest probabilities of lowest ICER versus Clb (the first best payoff) and highest QALY gain (the first best effectiveness). In addition, 
the potential cost-effectiveness was projected to be achievable with low to moderate willingness-to-pay thresholds when selecting GClb (ie, best overall value with reasonable willingness-to-pay thresholds). Furthermore, the value of conducting additional research to support decision-making or loss from making a wrong decision was low to moderate, and relative results were robust based on the 26 different scenario analyses. Finally, the developed CBA demonstrated the best relative clinical value, the lowest risk for high cost-benefit ratio, the best clinical value-cost-effectiveness relation, and the most value gained with the limited budget (highest impact on investment) for GClb. Both drug and PFS costs seemed to follow the clinical value of drug, but the trend decreased as a function of costs, meaning that more efficient drugs also had a lower cost-benefit ratio; this scenario was also observed in the key outcomes. Generally, the CBA results and key outcomes concurred, but additional CEAs with different cancer types are needed to assess the validity of CBA due to its inherent limitations.
CBA is a clinical value assessment method that can increase the clinical interpretation and appeal of results; however, it cannot fully substitute the primary outcomes of standard cost-effectiveness analysis. CBA may ignore differences in a number of cost categories (eg, treatment administration, monitoring, AEs, endstage treatment). Depending on the benefit side, it may also ignore the impact of QoL, AEs, and various types of survival parameters. If CBA is performed without further consideration, costs and benefits may be assessed from different timelines, and discounting can be ignored. Thus, CBA can easily result in investment biases and partial optimization of limited budgets. CBA as such should probably not be used as the primary method of analysis without acknowledging its limitations and their potential consequences, and its results should be interpreted with caution. In the present study, the objective of using CBA was only to elaborate and complement the primary and secondary outcomes.
The CBA provided new insights in the present study. All the primary, secondary, and tertiary findings were based on a decision-analytic modeling approach capable of synthesizing all the known evidence. With direct data elicitation methods or analysis of publications alone (eg, without handling of local age-and gender-specific mortality or without assessing the mean survival rates), CBA, as with any piggy-back assessment, may lack agreement between the benefits and costs and may not concur with solid standard modeled CEA results. Mean (not median) survival is the expected value of distribution; costs are usually means, 50 and with means, arithmetic calculations are feasible. As was performed in the present study, dose-response should be accounted for in the CBA. Consequently, CBA can offer new insights, although it is not a simple procedure; comprehensive methods and data are needed to conduct a valid CBA.
As observed before, treatment tolerability has an important role when the treatment response is not age related. 51 Since the early 1990s, the first and relapsed/ refractory line cost-effectiveness of CLL treatments have been modeled, [52] [53] [54] [55] [56] [57] and rituximab and bendamustine alone or as combinations with other treatments have been found to provide reasonable value for money. In this analysis, the ICER for RB versus Clb was €59,316/QALY gained, a result that was potentially not cost-effective.
Generally, health economic modeling results in the simplification of a more complex reality. The key sources of uncertainty in this study were model structure, parameter values (imprecision of parameters), and patient variability. We discuss these uncertainties in detail. First, the cost-effectiveness model had 3 key health states in which PFS was divided into on-and-off treatment, whereas other important factors such as Binet staging and treatment inconvenience were taken into account. However, the transition probabilities derived considered these health states as unique because of a lack of data.
In a previous study, 53 concerns were raised that a 3-state Markov model structure was too simplistic for CLL, which also applies for any simple data-based analysis. Alternative modeling approaches (eg, AUC modeling, in which overall survival is estimated on the basis of PFS by using PFS as a surrogate end point for overall survival and including a response for PFS health state) are available. However, long-term data on PFS and overall survival relationship, sample sizes, and potential interaction information between treatment and response were too sparse for the AUC or PFS responder status modeling. Most importantly, the selected approach unlikely benefits the most costeffective treatment (GClb) because the PFS Kaplan-Meier curves of GClb patients in CLL11 lay consistently above the RClb and Clb curves regardless of response class.
Second, a median PFS was reached in all 3 treatment arms in the latest CLL11 data-cut. However, there was still censoring and uncertainty about the best-fitting function and its tail for PFS, in particular for the GClb arm. The Weibull distribution was selected because it provided a good fit, had reasonable tail shape, resulted in conservative estimates, and enabled comparability with many other earlier CEAs. A limitation of the meta-analysis used for OClb and RB PFS estimation was the small number of trials found in the evidence network. To indirectly incorporate evidence via HR, the proportional hazards assumption should hold. This was checked by using standard techniques, which held reasonably in the CLL11 data. The relative results of this analysis were also agreeable with another recent meta-analysis. 58 However, the absolute results of this analysis were more conservative, potentially indicating that the effects and clinical value were not overestimated in the CEA or CBA. Furthermore, the scenarios with upper or lower 95% CI HR thresholds for the OClb and RB PFS confirmed that the cost-effectiveness of GClb is not volatile to indirect data. CLL11 data were not sufficiently mature to model PPS. Because it was unknown in CLL11 whether PPS depends on first-line treatment received, the same modeling approach for PPS was applied to all treatment arms. In the CLL5 trial, the effect of the first-line treatment was not statistically significant for the prediction of PPS. However, GClb patients will probably survive beyond the modeled overall survival in this CEA, given the recent overall survival data. 16 This result could further improve the cost-effectiveness of GClb.
CLL5 used the earlier progression definition, 59 whereas CLL11 used the updated progression definition. 60 The latter may be more sensitive because imaging techniques gained a higher weight, and cytopenia was added. However, the progression assessment in the CLL5 and CLL8 trials was rigorously conducted.
The QoL variables applied were not provided directly by the patients but were sourced through the utility elicitation study. Lack of accuracy risk in the vignettes was reduced by a staged approach with input from literature, patients, and health care professionals and by using the EQ-5D-3L dimensions. The interviewees were younger than the CLL11 patients, and thus all QoL values were anchored to Finland to capture the impact of comorbidities, age, and Finnish preferences. When the general Finnish population values 43 and previous cancer QoL studies [5] [6] [7] [8] 61, 62 were reviewed, there was no obvious discrepancy with the anchored QoL values.
None of the earlier CEAs included consideration of Binet stages, although they do have an impact on the treatment decisions. 13 Follow-up resource use was based on Finnish clinical practice, in line with recommendations, and specified for different Binet stages. These resource estimates were lower than recent study results, including a Danish study 12 and a German study using Elixhauser comorbidity scores and generalized estimating equations. 11 However, sensitivity analysis showed that these Finnish results could be generalized to a wider landscape, namely UK QoL and German resource use were used in sensitivity analysis scenarios and results were robust. The generalizability may also be good in countries with similar cost structures (most probably Nordic and maybe other European Union countries). The biggest cost drivers were drug or progression related, and those 2 seemed to have a tradeoff. If relative costs related to progression were high, drug costs and QALYs gained were low, and vice versa.
Third, Finnish experience and CLL11 individual patient data were used to define cohort characteristics, and patients were elderly when they entered PPS. The trial populations of CLL11 and CLL5 resembled each other, and their Binet staging was incorporated into the analysis. However, individual patient data were not available for OClb or RB. Age was adjusted in the network meta-analysis, but a risk of residual confounding due to the 17p deletion status and Binet stages remained. Patients included in the COMPLEMENT 1 study 32 were similar to CLL11 patients, with minor differences (they were younger and were more frequently at Binet stage A). In addition, when cumulative chlorambucil doses were compared, the dose in CLL11 was at the lower end (with circa 400 to 440 mg) compared with Knauf et al 14 (with circa 560 mg) or CLL5 (with circa 490 mg).
Thus far, there has been no publication of studies regarding the effects and cost-effectiveness of the changes in the CLL guidelines or response/progression criteria, optimal chlorambucil regimen, or sequential modeling of CLL (eg, Soini et al 46, 47 ). Studies regarding the importance of defining disease staging and clinical end points 63 , CBA and CEA relations, unconfounded PPS survival 38, 64 and societal willingness-to-pay 65 are also needed. From the conventional perspective of extrawelfarism (ie, maximize health benefits), and lacking data for per-patient incremental cost-effectiveness, these results indicate that GClb should be selected for the modeled patients, and the risk of making wrong decisions is minor in terms of efficiency and effectiveness. However, if the budget is not sufficient for all patients who need GClb, then an explicit target for PFS (and PFS QALYs) that is thought to be societally "enough PFS" for these patients should be set in a political decisionmaking process and the treatment mix optimized conditional on process.
CONCLUSIONS
With €30,000/QALY gained or higher thresholds, GClb was clearly the most cost-effective CLL treatment when RFC was unsuitable. In general, GClb provided the best value for money option in terms of relative and absolute outcomes. The low to moderate value of additional research or loss from a wrong decision was assessed.
ACKNOWLEDGMENTS
The study was funded by Roche Oy.
The authors thank Dr. Taru Kuittinen (Kuopio University Hospital) for the drug administration, monitoring and adverse event management expertise, and comments provided on the manuscript draft. They also thank Phuong Ngo (Roche Products Pty Limited), Joshua Ray (F. Hoffmann-La Roche Ltd), Taru Hallinen (ESiOR Oy) and Kaisa Tuppurainen (Roche Oy) for the comments provided on the manuscript draft.
Mr. Soini and Mrs. Hautala were responsible for study management; Mr. Soini provided study analysis and manuscript drafting and Dr., Adjunct Prof. Martikainen, Drs. Poikonen and Kyttälä, and Mrs. Hautala and Becker performed critical manuscript revisions. All authors were responsible for concept/design and study/analysis plans, as well as data assembly, and all authors gave final approval for the version to be published.
CONFLICTS OF INTEREST
Mr. Soini and Dr., Adjunct Prof. Martikainen are founding partners, employees, and board members of ESiOR Oy. ESiOR Oy conducts studies, statistical analysis, consultancy, education, reporting, and health economic evaluations for several pharmaceutical, food industry, diagnostics and device companies, hospitals, consultancies, and academic institutions. Mrs. Hautala was an employee of Roche Oy at the time of the study. Dr. Poikonen declares consultation fees (Roche), lecture fees (Novartis, Celgene, Baxter, and Glaxo-Smith-Kline), and meeting participation support (Novartis). Mrs. Becker is employed by F. Hoffmann-La Roche Ltd. Dr. Kyttälä was an employee of Roche Oy at the time of study. All authorship decisions were made on the basis of scientific consideration. The authors have indicated that they have no other conflicts of interest regarding the content of this article.
The study sponsor participated in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. 
SUPPLEMENTARY MATERIALS A: Patient Characteristics in Clinical Trials

B. Treatment Costs of Adverse Events
C: Scenario-Type Sensitivity Analyses
The following sensitivity analyses were implemented using the deterministic (mean value) modeling method.
Methods
Deterministic: base case results using deterministic modeling.
Undiscounted: No discounting of results was done. 10 year horizon: Time horizon was limited to 10 years in the modeling. 60 years, Binet stages 5%, 64% and 31% for A, B and C, respectively) and also PPS (exponential distribution's parameter values (standard errors): intercept 5.427 (0.533) and age -0.021 (0.008) 31 st October 2011 data cut)) was applied to test the sensitivity of the results to cohort characteristics ("generalizability" to a wider population).
Efficacy
Exponential PFS: PFS modeled based on exponential survival distribution. CLL11 AEs based on the publication [15] . Hospital perspective: estimated patient copayments and costs for reimbursed treatments (Clb) excluded.
Foreign resources: Resource use not related to drugs was based on a German study [11] . Table C1 . Figure D1 . Figure E1 . Supplemental Table C1 F. Multinomial Cost-Effectiveness Acceptability Curves Figure F1 .
Results
D. Modeled Quality-Adjusted Survivals
E. Cost Drivers by Treatment
G. Clinical Value Analysis (CVA)
Cost-Benefit Analysis (CBA, a type of CVAalso called as Drug Cost-Benefit Analysis, DCBA) was developed based on the decision analytical modelling results. For some parts, CBA can be more clinically appealing and easier to understand in practice than incremental costutility analysis. However, CBA has few inherent limitations which were shortly discussed in the main article.
The CBA with drug costs only included mean drug costs based on the actual first-line drugs consumed (wastage assumed) and ignored other (e.g. administration, monitoring, adverse event, end-stage) coststhe perspective of analysis was limited to oncologic drug payer perspective. PFS payer perspective results were reported as sensitivity analysis and included all mean PFS time direct costs. The clinical outcomes of CBA were also modelled as means.
Here, as examples, following tertiary outcomes were reported in terms of CBA:
Relative benefit assessment based on PFS years gained (includes the potential "trial value" of drug during PFS) and PFS QALYs gained (includes the potential "full value" of drug) Absolute benefit assessment (investment impact assessment, IIA) based on QALYs, and PFS and OS years gained with limited assumed drug budget of €20,000/ patient.
Results
As was observed based on the Table G1 and Figure G1 , CBA results concurred well with the key Supplemental Table C1 cost-utility analysis results reported in the main article. The results indicated the best relative clinical value and most efficient use of limited budget for GClb. Due to assumption of no survival benefits after progression, lifetime CBA and key results concurred less well with each other ( Figure G2 ).
When these results (Table G1 , Figure G1 and G2) were interpreted, caution was needed: the comparator for cost per benefit in average (i.e. not incremental) analysis was basically instant death [65] . Thus, the incremental relative benefit vs. Clb was plotted to the Figures G1-3 effective treatment was not selected and the cheapest or less effective option was taken. In this case, GClb was the most beneficial treatment and the loss of not choosing it was the biggest. In addition, the costbenefit ratio of GClb during progression-free time was the lowest, meaning that every euro with GClb produced the biggest effect. GClb resulted to best relative clinical value-cost-effectiveness relation. In order to assess the joint uncertainty around the results, relative benefitcost-effectiveness planes were shown below ( Figure G3 ) based on the probabilistic analysis.
Based on the Figure G3 , RB and OClb had high risk for higher costs per benefit when the results in comparison to Clb were poor or negative. GClb and RClb seemed to have low risk for higher costs per benefit. In patient level analysis, this observation could be used as a tool for indicating poorer cost per benefit ratio through the incremental benefit and multivariate methods.
Based on the probabilistic results of PFS costs and relative incremental PFS years in comparison to Clb, GClb resulted to the highest relative PFS in comparison to Clb with 99.9% probability based on Bayesian Treatment Ranking (BTR). RClb resulted to second highest relative PFS with 51.7% probability. RB resulted to third highest relative PFS with 78.6% probability.
Based on the probabilistic results of PFS costs and relative incremental PFS QALYs in comparison to Clb, GClb resulted to the highest relative PFS QALYs in comparison to Clb with 99.9% probability based on the BTR. RClb resulted to second highest relative PFS QALYs with 51.4% probability. RB resulted to third highest relative PFS QALYs with 80.5% probability.
Finally, PFS and QALY benefits gained with fixed limited drug and PFS cost budget of €20,000 were estimated (Table G1, Figure G4 ) in IIA. Based on these, obinutuzumabþchlorambucil resulted to longest benefits and made the best value of limited budgets. On the other hand, RB seemed to make the worst use of budgets (i.e. RB had the highest cost per benefit gained and lowest times with the fixed budget).
Based on the probabilistic results of PFS costs and PFS years, GClb resulted to the highest health impact on €20 000/patient investment ( 
Probability of cost-effectiveness
Probability of cost-effectiveness 48 000 45 000 42 000 39 000 36 000 33 000 30 000 27 000 24 000 21 000 18 000 15 000 12 000 9 000 6 000 3 000 48 000 45 000 42 000 39 000 36 000 33 000 30 000 27 000 24 000 21 000 18 000 15 000 12 000 9 000 6 000 3 000 0 0 Figure F1 . Multinomial cost-effectiveness acceptability curves (mCEAC) and cost-effectiveness acceptability frontier (CEAF) for comparison either including (higher part) or excluding (lower part) chlorambucil alone (Clb). In the comparison including (excluding) Clb, GClb was optimal and potentially cost-effective treatment with over 50% probability for cost-effectiveness with the threshold exceeding 29,558 (20,803) per QALY gained, respectively. In conclusion, the CBA demonstrated highest payoff for obinutuzumabþchlorambucil, when assessing only its drug costs or PFS costs. Generally, the both cost types seemed to follow the clinical value (mean PFS) of drug in this case, but the trend decreased as the function of costs meaning that more efficient drugs such as GClb had also lower cost-benefit ratio and higher health impact based on the investment. This may be a result of decreasing marginal benefit (an assumption in health economics) and price competition to be studied elsewhere. 
PFS QALYs in comparison to
QALYs with C 20,000 PFS costs QALYs with C20,000 drug costs PFS years with C20,000 PFS costs PFS years with C20,000 drug costs Figure G4 . IIA: PFS and QALY benefits gained with fixed limited oncological drug or PFS cost budget of 20,000/patient.
Detailed legend: IIA = impact investment analysis. PFS ¼ progression-free survival. QALY ¼ quality-
